Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11354590 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1CYP3A4ALOX15USP2 | |
| SCHEMBL9508203 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1CYP3A4ALOX15USP2 | |
| SCHEMBL7278345 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1CYP3A4ALOX15USP2 | |
| SCHEMBL30252278 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TDP1CYP3A4ALOX15USP2 | |
| SCHEMBL2231148 | 0.98 | ALDH1A1 (0.56) | ALDH1A1TDP1CYP3A4ALOX15USP2 | |
| SCHEMBL837175 | 0.91 | — | — | |
| Acetic Acid SCHEMBL9705698 | 0.89 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4ALOX15USP2 | |
| SCHEMBL7093157 | 0.89 | ALDH1A1 (0.70) | ALDH1A1TDP1CYP3A4ALOX15USP2 | |
| SCHEMBL7094868 | 0.87 | ALDH1A1 (0.67) | ALDH1A1TDP1CYP3A4ALOX15USP2 | |
| 1,5-Pentanediol SCHEMBL29013568 | 0.85 | CHRM2 (0.46) | ALDH1A1TDP1CYP3A4ALOX15USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215499-B1 | IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | EMERGENT VIROLOGY LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3215499-B1 | IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | EMERGENT VIROLOGY LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10428022-B2 | Iminosugars useful for the treatment of viral diseases | EMERGENT VIROLOGY LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428022-B2 | Iminosugars useful for the treatment of viral diseases | EMERGENT VIROLOGY LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180273473-A1 | IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. | 2018-09-27 | — | — | US | disclosed |
| EP-3215499-A1 | IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | Emergent Virology LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073652-A1 | IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | UNITHER VIROLOGY, LLC (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20140287024-A1 | NANOPARTICLE-BASED DELIVERY SYSTEM WITH OXIDIZED PHOSPHOLIPIDS AS TARGETING LIGANDS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | WANG SHU (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140287024-A1 | NANOPARTICLE-BASED DELIVERY SYSTEM WITH OXIDIZED PHOSPHOLIPIDS AS TARGETING LIGANDS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | WANG SHU (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428022-B2 | Iminosugars useful for the treatment of viral diseases | GBA1, MAN2B1, GBA2 | ALDH1A1 1770/4885TDP1 2343/4885CYP3A4 3573/4885 |
| US-20180273473-A1 | IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | GBA1, MAN2B1, GBA2 | ALDH1A1 1770/4885TDP1 2343/4885CYP3A4 3573/4885 |
| US-20140287024-A1 | NANOPARTICLE-BASED DELIVERY SYSTEM WITH OXIDIZED PHOSPHOLIPIDS AS TARGETING LIGANDS FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS | LDLR, APOB, MSR1 | ALDH1A1 3121/4885TDP1 4584/4885CYP3A4 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.